Plus Therapeutics, Inc. (NASDAQ: PSTV) shares went skyward Thursday, on word its CNSide Diagnostics, subsidiary of Plus Therapeutics, Inc. has signed a national agreement with UnitedHealthcare Insurance Company (NYSE: UNH), effective September 15, covering over 51 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test (LDT).
The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.
More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases.
This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.
Headquartered in Houston, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes.
PSTV shares flew 18 cents, or 43.7%, to 58 cents, while those for UNH slid $6.64, 1.9%, to $345.08.
